Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

Kourtney Kardashian’s new “GLP-1 Daily” pill is the latest product to capitalize on the weight loss drug craze.

In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...

A Swiss pharmaceutical company hoping to cash in on the weight loss drug trend is having its dreams dashed amid new trials ...

At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...

Novo Nordisk (NVO) stock is falling Friday morning after the pharmaceutical giant shared that additional weight loss tied to ...

Weight loss injections are essentially the opposite of pills in terms of pros and cons. They’re generally more effective and ...

The weight-loss market is heating up as a number of companies are looking for a way to upend the dominance of market leaders Novo Nordisk ( NVO) and Eli Lilly ( LLY) by introducing GLP-1 pills.

Novo Nordisk’s American depositary receipts tumbled almost 6% Friday after the drugmaker reported mixed results from a study of an experimental weight-loss pill. The pill, monlunabant, helped people ...

Epitomee Medical (TASE: EPIT), chaired by serial biomed entrepreneur Shimon Eckhouse, has announced the receipt of US Federal ...

Roche provided early Phase 1 clinical trial data last week that showed its pill provided 6.1% weight loss over four weeks. The sample size of the study was small, just 12 patients, which is ...